Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, shares the findings from a study investigating FDG-avidity in extranodal marginal zone lymphoma (EMZL). Dr Alderuccio explains that the study analyzed PET/CT scans from patients with EMZL and found that, in over 70% of cases, EMZL was an FDG-avid disease. Dr Alderuccio also discusses the relationship between FDG-avidity and tumor location, as well as the correlation between FDG-avidity and tumor size, and uses these results to explain why some cases were not FDG-avid. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
